# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Hepatitis

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 131-140 of 500 results.
Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients
Status: Recruiting
Last Changed: Nov 12, 2020
First Received: Jun 02, 2020
Disease(s): Hepatitis C, Telemedicine
Intervention(s): Telemedicine
Locations: Hospital Universitario de Canarias, La Laguna, Santa CRUZ DE Tenerife, Spain
Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B
Status: Recruiting
Last Changed: Nov 12, 2020
First Received: Dec 26, 2019
Disease(s): Hepatitis B, Chronic, Pregnancy Related
Intervention(s): Tenofovir Alafenamide 25 MG for arm (A), Tenofovir Disoproxil Fumarate 300mg for arm (B)
Locations: Pingdingshan Hospital of Chongqing Public Health Medical Treatment Center, Shapingba, Chongqing, China
Hainan General Hospital, Haikou, Hainan, China
The Third Hospital of Qinhuangdao, Qinhuangdao, Hebei, China
The Fourth Hospital of Harbin Medical University, Harbin, Heilonjiang, China
Xiangya Hospital, Central South University, Changsha, Hunan, China
... and 2 other locations.
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
Status: Recruiting
Last Changed: Sep 10, 2020
First Received: Sep 10, 2020
Disease(s): Chronic Hepatitis b
Intervention(s): Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet, Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate
Locations: The First Hospital of Jilin University, Changchun, Jilin, China
Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms.
Status: Recruiting
Last Changed: Jul 18, 2018
First Received: May 14, 2018
Disease(s): Hepatitis E Infection in Humans and in Environment
Intervention(s): Only advice for diagnosis and prevention
Locations: Schvoerer, Vandoeuvre Les Nancy, France
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
Status: Recruiting
Last Changed: Oct 29, 2020
First Received: Jul 14, 2017
Disease(s): Autoimmune Hepatitis
Intervention(s): VAY736, Placebo
Locations: Novartis Investigative Site, Coronado, California, United States
Novartis Investigative Site, Rialto, California, United States
Novartis Investigative Site, Sacramento, California, United States
Novartis Investigative Site, Denver, Colorado, United States
Novartis Investigative Site, Lakewood Ranch, Florida, United States
... and 54 other locations.
Immunology of HIV and Alcoholic Hepatitis
Status: Not yet recruiting
Last Changed: Feb 11, 2020
First Received: May 15, 2019
Disease(s): HIV/AIDS, Alcoholic Hepatitis
Intervention(s): Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
Locations: Infectious Diseases Research Center, Indianapolis, Indiana, United States
To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.
Status: Not yet recruiting
Last Changed: Dec 19, 2018
First Received: Dec 11, 2018
Disease(s): Hepatitis B
Intervention(s): Nucleotide Analog, Interferon Alfa-2A
Locations: Chan Xie, Guangzhou, Guangdong, China
The Hepatitis C Transplant Collaborative
Status: Recruiting
Last Changed: Oct 08, 2020
First Received: Jul 30, 2020
Disease(s): Transplant; Failure, Heart, Hepatitis C
Locations: Baylor Scott & White health research institute, Dallas, Texas, United States
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
Status: Recruiting
Last Changed: Oct 08, 2020
First Received: Jan 28, 2019
Disease(s): Liver Transplant, Hepatitis C
Intervention(s): sofosbuvir/velpatasvir
Locations: UPMC, Pittsburgh, Pennsylvania, United States
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients
Status: Not yet recruiting
Last Changed: Jul 21, 2020
First Received: Jul 21, 2020
Disease(s): Chronic Hepatitis B
Intervention(s): HRS5091